Juno Therapeutics
Juno is a biopharmaceutical company that researches and develops cellular immunotherapies for the treatment of cancer.
Business Model:
Revenue: $106M
Employees: 501-1,000
Industries / Tags:
Detailed Juno Therapeutics Information
Juno Therapeutics was acquired by
Celgene.
The acquisition happend on 2018-01-22.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 400 Dexter Avenue North
City: Seattle
State: WA
Zip: 98109
Country: US
Financial Info
Stage:
series b
Raised Last:
$134M
Raised Total:$310M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Juno is a biopharmaceutical company that researches and develops cellular immunotherapies for the treatment of cancer.
Contact Phone:
+12065821600
Contact Email:
Juno Therapeutics went public on 12/19/2014 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
12/19/2014
IPO Valuation:
$2B
Ticker Symbol:
JUNO
IPO Price:
$24/share
Amount Raised:
$265M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2020 | JW Therapeutics | Series B | 0 |
| 5/2015 | Editas Medicine | Funding Round | 0 |
| 3/2018 | JW Therapeutics | Series A | 0 |
| 6/2020 | JW Therapeutics | Series B | 0 |
| 3/2018 | JW Therapeutics | Series A | 0 |
| 5/2015 | Editas Medicine | Funding Round | 0 |
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2015 | Equity | $896.8M |
Venrock ARCH Venture Partners |
8/2014 | Series B | 4 | $134M |
ARCH Venture Partners Bezos Expeditions Venrock Alaska Permanent Fund ARCH Venture Partners Bezos Expeditions Venrock Alaska Permanent Fund |
4/2014 | Series A | $176M |
ARCH Venture Partners Alaska Permanent Fund Bezos Expeditions Venrock |
12/2013 | Series A | 2 | $120M |
Alaska Permanent Fund ARCH Venture Partners Alaska Permanent Fund ARCH Venture Partners |
9/2017 | Equity | $31.1M |
Venrock ARCH Venture Partners |
4/2014 | Series A | 2 | $56M |
Venrock Bezos Expeditions Bezos Expeditions Venrock Venrock Bezos Expeditions Bezos Expeditions Venrock |
7/2014 | Series B | $134M |
ARCH Venture Partners |
12/2014 | IPO | $264.6M |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 7/2016 | RedoxTherapies | |
| 6/2016 | Contura | |
| 1/2016 | AbVitro | |
| 6/2015 | X BODY | |
| 5/2015 | Stage Cell Therapeutics |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
